

BELLICUM PHARMACEUTICALS, INC
 Form 4/A
 June 19, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Spencer David M.

2. Issuer Name and Ticker or Trading Symbol
 BELLICUM
 PHARMACEUTICALS, INC
 [BLCM]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director
 Officer (give title below)
 ___ 10% Owner
 ___ Other (specify below)
 Chief Scientific Officer

(Last) (First) (Middle)

C/O BELLICUM
 PHARMACEUTICALS, INC., 2130
 W. HOLCOMBE BLVD., STE. 800

3. Date of Earliest Transaction
 (Month/Day/Year)
 06/16/2015

4. If Amendment, Date Original Filed
 (Month/Day/Year)
 06/18/2015

6. Individual or Joint/Group Filing (Check Applicable Line)
 Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

HOUSTON, TX 77030

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Common Stock	06/16/2015		S(1)		17,200	D	\$ 22.8227 (2)
							166,400 (3)
Common Stock	06/16/2015		S(1)		2,800	D	\$ 23.7939 (4)
							163,600 (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form 4/A

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$23.52 to \$24.07. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.